AMPE Key Stats
- Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Confe... May 13
- AMPIO PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 3
- Ampio Pharma Initiates Phase III, Investors Extend Momentum May 3
- Major Pharma Companies Refocus R&D Efforts, Aim to Replace Lost Revenues: Expert... Apr 30
- Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in O... Apr 25
- AMPIO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive... Apr 4
- Lucrative AMD And DME Markets Attract Wall Street To Regeneron And Other Players Apr 3
- 4 Healthcare Stock Stories for Tuesday Investment Wellness Apr 2
- Stocks Maintain Early Lead; Drugmakers Alexion, Regeneron Climb Apr 2
- Ampio's Eye Drug Trial Design Won't Pass FDA Muster Apr 2
AMPE Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Ampio Pharmaceuticals is up 88.39% over the last year vs S&P 500 Total Return up 31.68%, AcelRx Pharmaceuticals up 85.56%, and Siga Technologies up 50.42%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for AMPE
Pro Report PDF for AMPE
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download AMPE Pro Report PDF
Pro Strategies Featuring AMPE
Did Ampio Pharmaceuticals make it into our Pro Portfolio Strategies?